2 citations,
February 2024 in “Journal of the European Academy of Dermatology and Venereology” The study created a 27-item measure to assess the impact of skin diseases.
September 2024 in “Journal of the American Academy of Dermatology” Experts agree on guidelines for safely using low-dose oral minoxidil to treat hair loss.
November 2024 in “JAMA Dermatology” An international expert consensus statement was developed to guide the off-label use of low-dose oral minoxidil (LDOM) for hair loss, involving 43 dermatologists from 12 countries. Through a modified Delphi process, consensus was reached on 76 items, including diagnoses, dosing for adults and adolescents, contraindications, and monitoring. However, consensus was not achieved for pediatric use and titration protocols. The statement aims to assist clinical practice until more data are available, highlighting the need for further research on pediatric use, comparative efficacy with topical minoxidil, long-term safety, and other off-label minoxidil forms.
1 citations,
January 2024 in “NPJ breast cancer” Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
October 2015 in “Annals of Internal Medicine” Dutasteride, fesoterodine, and finasteride help older patients with urinary issues.